Moderna (MRNA) Liabilities and Shareholders Equity (2017 - 2026)

Moderna (MRNA) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $11.5 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $11.5 billion, down 9.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.0 billion (down 17.76% YoY), and the FY2025 annual result was $12.3 billion, down 12.76% from the prior year.
• Liabilities and Shareholders Equity eased to $11.5 billion in Q1 2026 per MRNA's latest filing, from $12.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $27.6 billion in Q1 2022 and troughed at $11.5 billion in Q1 2026.
• A 5-year average of $18.4 billion and a median of $16.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 117.5% in 2022, then slumped 30.66% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $25.9 billion in 2022, then decreased by 28.74% to $18.4 billion in 2023, then fell by 23.25% to $14.1 billion in 2024, then decreased by 12.76% to $12.3 billion in 2025, then fell by 6.89% to $11.5 billion in 2026.
• Business Quant data shows MRNA's Liabilities and Shareholders Equity at $11.5 billion in Q1 2026, $12.3 billion in Q4 2025, and $12.1 billion in Q3 2025.